Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|34|4972-4979

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.34, 2015-10, pp. : 4972-4979

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial (Thematic Issue: Disorders of Consciousness: Recent Advances in Neurobiology and Treatments)

By  

Current Pharmaceutical Design, Vol. 20, Iss. 26, 2014-08 ,pp. : 4119-4120

Bentham Science Publishers

Access to resources Recommend Favorite

Neurobiology of antidepressant treatments

By de Montigny C.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 262-262

Elsevier

Access to resources Recommend Favorite

The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome

By  

Current Neuropharmacology, Vol. 12, Iss. 1, 2014-01 ,pp. : 71-98

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted treatments for cirrhosis

By Fallowfield Jonathan A   Iredale John P  

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 5, 2004-10 ,pp. : 423-435

Informa Healthcare

Access to resources Recommend Favorite

EDITORIAL [Hot Topic: Molecularly Targeted Treatments for Colorectal Cancer: Advances and Limitations (Guest Editor: Silvio Parodi)]

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 301-302

Bentham Science Publishers

Access to resources Recommend Favorite